BioCryst/$BCRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioCryst
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Ticker
$BCRX
Sector
Primary listing
Employees
580
Headquarters
Website
BioCryst Metrics
BasicAdvanced
$1.7B
-
-$0.18
1.10
-
Price and volume
Market cap
$1.7B
Beta
1.1
52-week high
$11.31
52-week low
$6.02
Average daily volume
2.8M
Financial strength
Current ratio
2.249
Quick ratio
1.982
Long term debt to equity
-166.314
Total debt to equity
-183.501
Interest coverage (TTM)
0.59%
Profitability
EBITDA (TTM)
58.507
Gross margin (TTM)
66.48%
Net profit margin (TTM)
-6.41%
Operating margin (TTM)
9.95%
Effective tax rate (TTM)
-10.92%
Revenue per employee (TTM)
$960,000
Management effectiveness
Return on assets (TTM)
7.46%
Return on equity (TTM)
7.96%
Valuation
Price to revenue (TTM)
2.954
Price to book
-3.66
Price to tangible book (TTM)
-3.94
Price to free cash flow (TTM)
104.478
Free cash flow yield (TTM)
0.96%
Free cash flow per share (TTM)
0.076
Growth
Revenue change (TTM)
45.85%
Earnings per share change (TTM)
-75.47%
3-year revenue growth (CAGR)
39.90%
10-year revenue growth (CAGR)
29.71%
3-year earnings per share growth (CAGR)
-46.33%
10-year earnings per share growth (CAGR)
-8.33%
What the Analysts think about BioCryst
Analyst ratings (Buy, Hold, Sell) for BioCryst stock.
Bulls say / Bears say
ORLADEYO net revenue in Q2 2025 grew 45% year-over-year, reaching $156.8 million. This led to total revenue of $163.4 million and a 239% increase in operating profit to $29.8 million.
BioCryst paid off $50 million in term debt in Q2 and says it will pay off all remaining term debt using sale proceeds from its European ORLADEYO unit, cutting future interest costs and improving its balance sheet.
The company kept its full-year 2025 ORLADEYO revenue guidance at $580 million to $600 million, backed by record new patient prescriptions, more prescribers, and U.S. sales making up 89.5% of global net revenue.
ORLADEYO made up about 96% of Q2 product sales, meaning BioCryst faces high single-product concentration risk—if demand drops, revenue could be hit.
Selling its European ORLADEYO business to Neopharmed Gentili for up to $264 million means BioCryst loses a direct presence in Europe and future European revenue, which could limit growth opportunities.
BioCryst shares are trading at roughly 25 times next-12-month earnings—a premium to the biotech sector average—implying the stock could be overvalued and exposed if growth targets aren’t met.
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
BioCryst Financial Performance
Revenues and expenses
BioCryst Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioCryst stock?
BioCryst (BCRX) has a market cap of $1.7B as of September 13, 2025.
What is the P/E ratio for BioCryst stock?
The price to earnings (P/E) ratio for BioCryst (BCRX) stock is 0 as of September 13, 2025.
Does BioCryst stock pay dividends?
No, BioCryst (BCRX) stock does not pay dividends to its shareholders as of September 13, 2025.
When is the next BioCryst dividend payment date?
BioCryst (BCRX) stock does not pay dividends to its shareholders.
What is the beta indicator for BioCryst?
BioCryst (BCRX) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.